secwatch.observer — SEC 8-K summary
======================================

Issuer:     Boundless Bio, Inc. (BOLD)
CIK:        0001782303
Form:       8-K
Filed at:   2024-12-12T23:59:59+00:00
Accession:  0000950170-24-135768
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boundless Bio stops BBI-825 trial, CMO and CBO depart; cash runway extends to 2027
--------------------------------------------------------------------------------

- BBI-825 Phase 1/2 STARMAP trial discontinued due to lack of dose-proportional PK, increased development costs, and competitive landscape changes.
- BBI-355 Phase 1/2 POTENTIATE trial on track for initial clinical data readout in H2 2025; enrollment ongoing.
- Third ecDTx program targeting a kinesin for ecDNA segregation; development candidate nomination expected mid-2025, IND in H1 2026.
- CMO Klaus Wagner and CBO Neil Abdollahian departing; James Freddo named Interim CMO while search for permanent CMO begins.
- Cash, equivalents, and short-term investments sufficient to fund operations into 2027 through anticipated milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782303/000095017024135768/0000950170-24-135768-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782303/000095017024135768/bold-20241206.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-135768

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer